Characteristic | Patients with AxPsA at First Clinic Visit, n = 50 | Patients without AxPsA at First Clinic Visit, n = 156 |
---|---|---|
Male/female | 31/19 | 88/68 |
Age, yrs* | 40.9 (11.9) | 42.8 (12.7) |
European ethnicity (%) | 49 (98) | 154 (99) |
Duration of psoriasis, yrs* | 13.6 (10.6) | 13.5 (11.5) |
Duration of PsA, yrs* | 8.6 (7.9) | 6.0 (6.9) |
Family history of psoriasis (%) | 17 (34) | 63 (40) |
Family history of PsA (%) | 1 (2) | 17 (11) |
Prior NSAID use (%) | 24 (48) | 86 (55) |
Prior DMARD use (%) | 19 (38) | 47 (30) |
Smoker (%) | 12 (24) | 35 (22) |
Hypertension (%) | 3 (6) | 16 (10) |
No. of actively inflamed joints* | 11.1 (8) | 11.4 (9.6) |
No. of swollen joints* | 3.6 (3.5) | 3.7 (4.6) |
No. of clinically damaged joints* | 10.1 (15.2) | 2.8 (6.9) |
Psoriatic nail dystrophy (%) | 44 (88) | 118 (76) |
Dactylitis (%) | 15 (30) | 64 (41) |
Enthesitis (%) | 13 (26) | 33 (21) |
No. of radiographically damaged joints* | 11.4 (12.5) | 3.5 (5.8) |
Periostitis (%) | 10 (20) | 22 (14) |
Calcaneal spurs (%) | 21 (42) | 56 (36) |
ESR* | 38.8 (25.9) | 25 (19.5) |
Positive rheumatoid factor (%) | 4 (8) | 8 (5) |
HLA-B*27 (%) | 15 (30) | 15 (10) |
↵* Mean (standard deviation). AxPsA: axial psoriatic arthritis; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate.